107 related articles for article (PubMed ID: 27853379)
1. FAS and FASL genetic polymorphisms impact on clinical outcome of malignant pleural mesothelioma.
El-Hamamsy M; Ghali RR; Saad AS; Shaheen SM; Salem AM
Onco Targets Ther; 2016; 9():6857-6863. PubMed ID: 27853379
[TBL] [Abstract][Full Text] [Related]
2. Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.
Powrózek T; Kowalski DM; Krawczyk P; Ramlau R; Kucharczyk T; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Dyszkiewicz W; Krzakowski M; Milanowski J
Clin Lung Cancer; 2014 Nov; 15(6):455-65. PubMed ID: 25246386
[TBL] [Abstract][Full Text] [Related]
3. A novel mechanism of rs763110 polymorphism contributing to cervical cancer risk by affecting the binding affinity of C/EBPβ and OCT1 complex to chromatin.
Wu S; Wang S; Fu Y; Tang W; Jin H; Meng Q; Zhang C; Cui M; Cao X; Li X; Zhang Z; Chen R
Int J Cancer; 2017 Feb; 140(4):756-763. PubMed ID: 27790710
[TBL] [Abstract][Full Text] [Related]
4. Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females.
Wang M; Wang Z; Wang XJ; Jin TB; Dai ZM; Kang HF; Guan HT; Ma XB; Liu XH; Dai ZJ
Drug Des Devel Ther; 2016; 10():2359-67. PubMed ID: 27524883
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
6. [Influence of apatinib and VEGFR2-906T>C polymorphism on clinical outcomes of advanced non-small cell lung cancer patients].
Zhao RH; Zhou YN; Li H; Li R; Zhang WJ; Zong H
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):105-110. PubMed ID: 30669747
[No Abstract] [Full Text] [Related]
7. Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.
Li Y; Hao YL; Kang S; Zhou RM; Wang N; Qi BL
Gynecol Oncol; 2013 Mar; 128(3):584-9. PubMed ID: 23234803
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
10. FASL polymorphism is associated with response to bacillus Calmette-Guérin immunotherapy in bladder cancer.
Lima L; Ferreira JA; Tavares A; Oliveira D; Morais A; Videira PA; Medeiros R; Santos L
Urol Oncol; 2014 Jan; 32(1):44.e1-7. PubMed ID: 23948181
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
Lopci E; Zucali PA; Ceresoli GL; Perrino M; Giordano L; Gianoncelli L; Lorenzi E; Gemelli M; Santoro A; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
[TBL] [Abstract][Full Text] [Related]
12. [Influence of polymorphisms of VEGFR2 on clinical outcomes and safety of advanced non-small-cell lung cancer treated by first line Bevacizumab plus chemotherapy regimens].
Fan HJ; Yuan J; Wu JJ; Jia YX; Ma YH; Li XY
Zhonghua Yi Xue Za Zhi; 2019 Jan; 99(2):99-104. PubMed ID: 30669746
[No Abstract] [Full Text] [Related]
13. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer.
Sung WW; Wang YC; Cheng YW; Lee MC; Yeh KT; Wang L; Wang J; Chen CY; Lee H
Clin Cancer Res; 2011 Sep; 17(18):5991-9. PubMed ID: 21807637
[TBL] [Abstract][Full Text] [Related]
14. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey.
Zucali PA; Simonelli M; Michetti G; Tiseo M; Ceresoli GL; Collovà E; Follador A; Lo Dico M; Moretti A; De Vincenzo F; Lorenzi E; Perrino M; Giordano L; Farina G; Santoro A; Garassino M
Lung Cancer; 2012 Mar; 75(3):360-7. PubMed ID: 21937142
[TBL] [Abstract][Full Text] [Related]
15. Polymorphisms of the FAS and FASL genes and risk of breast cancer.
Wang W; Zheng Z; Yu W; Lin H; Cui B; Cao F
Oncol Lett; 2012 Mar; 3(3):625-628. PubMed ID: 22740964
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of apoptosis-related gene functional variants in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
Tao KY; Li XX; Xu WZ; Wang Y; Zhu SM; Xie HX; Luo WH; Xu YJ; Xu XL
Onco Targets Ther; 2015; 8():147-55. PubMed ID: 25609982
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.
Zucali PA; Giovannetti E; Destro A; Mencoboni M; Ceresoli GL; Gianoncelli L; Lorenzi E; De Vincenzo F; Simonelli M; Perrino M; Bruzzone A; Thunnissen E; Tunesi G; Giordano L; Roncalli M; Peters GJ; Santoro A
Clin Cancer Res; 2011 Apr; 17(8):2581-90. PubMed ID: 21262916
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
[TBL] [Abstract][Full Text] [Related]
19. FasL -844T/C and Fas -1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances.
Zhao H; Chen W; Du P; Sun A; Zhuang C; Tong J; Wang L
Tumour Biol; 2015 Jun; 36(6):4319-26. PubMed ID: 25596086
[TBL] [Abstract][Full Text] [Related]
20. Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Edathara PM; Gorre M; Kagita S; Vuree S; Cingeetham A; Nanchari SR; Meka PB; Annamaneni S; Digumarthi RR; Satti V
Tumour Biol; 2016 Apr; 37(4):5475-84. PubMed ID: 26563376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
